Proadrenomedullin as indicator for renal replacement therapy in critically ill patients

Abstract

The present invention relates to a method for assessing whether a critically ill subject is in need of a renal replacement therapy, wherein the method comprises determining in a sample obtained from said subject the level of proadrenomedullin (proADM) or a fragment thereof, preferably the fragment is MR-proADM, wherein said level of proADM or the fragment thereof is indicative of a need of said subject to receive a renal replacement therapy.

Description

technical field [0001] The present invention relates to a method for assessing the need for renal replacement therapy in a critically ill subject. The assessment is based on the level of proadrenomedullin (proADM) or a fragment thereof, such as MR-proADM, in the subject's sample. Background technique [0002] Intensive care professionals are challenged every day to provide the best quality of care for critically ill patients at high risk of dying most often from multiple organ dysfunction syndrome (MODS) (Mayr, V.D., M.W. Dünser et al. (2006), Crit Care 10(6):R154). Renal dysfunction constitutes an important component in MODS and renal support is increasingly used routinely in the intensive care unit (ICU). Sepsis is a major cause of acute renal failure in critically ill patients (Bagshaw, S.M., S. Uchino et al. (2007), Clin J Am Soc Nephrol 2(3):431-439). About half of all patients with septic shock develop renal failure, which is associated with an increased mortality r...

AI Technical Summary

Problems solved by technology

Despite evidence that starting RRT earlier after an indication for treatment improves patient outcomes compared with delayed or later initiation, clear guidelines on the timing of RRT are lacking (Pannu 2005 (supra); Palevsky, P.M. ( 2008), Crit Care Med 36(4 Suppl):S224-228; Ricci 2016(supra))

Images